Read our COVID-19 research and news.

Webinar Technology

Protein biomarkers and cardiovascular / cardiometabolic disease: Better prediction, deeper understanding

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Protein biomarkers and cardiovascular / cardiometabolic disease: Better prediction, deeper understanding

Recorded 22 May 2019


Despite great advances in the understanding and treatment of cardiovascular disease (CVD), as well as widespread education around proactive preventive measures, it remains an enormous global healthcare issue, causing almost 18 million deaths annually. While clinical parameters (blood pressure, circulating lipid levels, body mass index) and lifestyle risk factors (smoking, lack of exercise) are well known, additional biomarkers are needed for improved risk assessment, more accurate diagnosis/prognosis, and a clearer understanding of the underlying pathophysiology of CVD. Protein biomarkers such as troponin I and NT-proBNP (N-terminal pro–B-type natriuretic peptide) have been long established, while advanced proteomic technologies are enabling new biomarker discoveries that promise to provide insights into disease pathways and mechanisms, and to offer a better understanding of the links between diseases (e.g., between cardiovascular and metabolic conditions). Identification of multiprotein signatures may provide more reliable clinical tools than can be devised using single markers, while combining protein biomarkers with other 'omics approaches and sophisticated data analysis techniques holds enormous potential for the development of precision medicine within the CVD/cardiometabolic fields.

During the webinar, the speakers will:

  • Explain how identification of new protein biomarkers enables better understanding, diagnosis, and outcome prediction in cardiovascular/cardiometabolic disease
  • Describe how combining machine learning with targeted proteomics can outperform existing clinical risk assessment criteria for coronary heart disease
  • Reveal new proteomic biomarkers of incident cardiometabolic diseases and explain how the integration of genetic information with model system studies can uncover novel pathways that may contribute to disease pathogenesis
  • Answer your questions during the live broadcast!

This webinar will last for approximately 60 minutes.

Speaker bios

Michiel J. Bom, M.D.

VU University Medical Center Amsterdam
Amsterdam, Netherlands

Dr. Bom received his M.D. from the University of Groningen in The Netherlands in 2014. He is currently working as a research fellow in the cardiology department of VU University Medical Center Amsterdam, Amsterdam University Medical Center (UMC), under the supervision of Paul Knaapen. He has published several papers on the topic of noninvasive cardiac imaging, specifically on quantitative positron emission tomography (PET) perfusion imaging and coronary computed tomography (CT) angiography. He is also investigating the role of proteomics in cardiovascular disease in a collaborative project with the vascular medicine laboratory of Erik Stroes at Amsterdam UMC’s Academic Medical Center.

Robert E. Gerszten, M.D.

Beth Israel Deaconess Medical Center
Boston, MA

Dr. Gerszten is chief of cardiology at Beth Israel Deaconess Medical Center, the Herman Dana Professor of Medicine at Harvard Medical School, and a senior associate member of the Broad Institute, all located in Boston, Massachusetts. He graduated from the Johns Hopkins University School of Medicine and completed his residency at the Hospital of the University of Pennsylvania and a clinical fellowship in cardiology at Massachusetts General Hospital (MGH). He also performed research fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and the Cardiovascular Research Center at MGH. Dr. Gerszten’s investigations focus on the nexus of cardiac and metabolic diseases. His translational research program leverages metabolomics and proteomics technologies for the discovery of new biomarkers and pathways contributing to atherogenesis and its complications. His highly collaborative program extends across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study, the Jackson Heart Study, the Diabetes Prevention Program, and the Thrombolysis in Myocardial Infarction (TIMI) Study Group. His work has been funded by the U.S. National Institutes of Health and the American Heart Association, from whom he received an Established Investigator Award. Dr. Gerszten is a member of the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists. He is a recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here